Sarepta's second shot at showing its Duchenne gene therapy delivers positive data but underwhelms — shares tumble

When Sarepta revealed last January that its gene therapy for Duchenne muscular dystrophy had failed the key functional endpoint in Part 1 of a …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sarep­ta's sec­ond shot at show­ing its Duchenne gene ther­a­py de­liv­ers pos­i­tive da­ta but un­der­whelms — shares tum­ble